Our goal should be to make lymphedema a preventable aspect of cancer survivorship or at a minimum, manageable, rather than a debilitating aftereffect that diminishes patients' quality of life.
We should use AI to develop recommendations for breast cancer screening protocols based on quantified risk, factoring in family history, ethnicity, genetics, and density, et al. – and then support the use of powerful new imaging AI technologies for those cases that demand a deeper look.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Providers should incorporate mental health screenings as a standard part of cancer care for patients and their loved ones.
March is Lymphedema Awareness Month, and today there are more options than ever to help prevent this challenging and all too common complication associated with breast cancer treatment.
While the past several decades have seen progress in early detection, recent innovations in metastatic breast cancer—or cancer that has spread to distant parts of the body, including the bone, brain, or lungs—continues to cause excitement.
The shift towards digital pathology has marked a significant advancement in breast cancer diagnosis. High-resolution digital imaging of slides provides pathologists with an unprecedentedly clear and expansive view of tissue samples for their analysis.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
At RSNA 2023, GE HealthCare announced the launch of a new AI suite designed to simplify radiologists’ workflows when reading mammograms and help them detect breast cancer in patients sooner. The new offering includes three AI tools made by iCAD.
BeiGene is expanding its cancer drug pipeline, landing global rights to an Ensem Therapeutics cancer drug candidate ready to enter the clinic. The drug targets CDK2, an enzyme whose excessive activity is associated with cancer progression.
The FDA approved AstraZeneca’s Truqap as a new treatment for advanced cases of breast cancer. The drug is the first in a new class of therapies addressing AKT genetic alterations.
We need more research and consideration of other approaches to cancer treatment and development of new therapies that better account for the quality of life of cancer patients.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Roche is acquiring global rights to a Zion Pharma Limited drug candidate with potential applications treating breast cancer that has metastasized to the brain. The small molecule, currently in Phase 1 testing, is designed to penetrate the blood-brain barrier.
Oncology Ventures recently announced investments in three cancer startups — VivorCare, Gabbi and Health Universe. The fund's founding partner said each company demonstrated an ability to tackle a specific problem within the cancer care space, such as enabling earlier breast cancer diagnoses and providing personalized care plans for cancer survivors.
Gilead Sciences drug Trodelvy is now approved for treating patients whose breast cancer is classified as HR positive and HER2 negative, expanding use of the drug to a much wider group of patients. In other regulatory approval news, use of a Takeda Pharmaceutical rare disease drug has expanded to younger children.
Orserdu, a drug from Menarini Group subsidiary Stemline Therapeutics, is now approved for treating breast cancers that carry the ESR1 mutation. The drug is the first approved oral therapy from a class of therapies called selective estrogen receptor degraders (SERDs).
Medical device manufacturer iCAD entered into a development and commercialization agreement with Google Health, in which it will integrate Google’s mammography AI technology into its suite of breast imaging AI products. The agreement marks Google’s first commercial partnership to deploy its breast imaging AI model into clinical practice.